PaxMedica, Inc. (NASDAQ:PXMD – Get Free Report)’s share price traded down 4.6% on Tuesday . The company traded as low as $0.21 and last traded at $0.21. 16,999 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 1,320,100 shares. The stock had previously closed at $0.22.
PaxMedica Price Performance
The business’s 50-day moving average is $0.36 and its two-hundred day moving average is $0.53.
PaxMedica (NASDAQ:PXMD – Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). On average, equities analysts forecast that PaxMedica, Inc. will post -1.09 EPS for the current year.
PaxMedica Company Profile
PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome.
See Also
- Five stocks we like better than PaxMedica
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Progress Software Stock Back in the Green After Beating Forecasts
- EV Stocks and How to Profit from Them
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.
